---
type: archive-record
title: PHAROS Invention Disclosure — V12 Evidence Bundle
aliases:
- archive/PHAROS Invention Disclosure Bundle Sources 2026-04-25/COVER_LETTER_FOR_COUNSEL
tags:
- archive
- pharos
- archive-record
- pharos-invention-disclosure-bundle-sources-2026-04-25
- counsel
- filing
- disclosure
- bundle
- inventor
- color-green
status: archived
created: '2026-04-25'
updated: '2026-06-26'
vault_area: archive
canonical_path: archive/PHAROS Invention Disclosure Bundle Sources 2026-04-25/COVER_LETTER_FOR_COUNSEL.md
backlink_count: 1
backlinks:
- '[[wiki/Orphan Index — Vault-Level Graph Repair 2026-05-06]]'
---

# PHAROS Invention Disclosure — V12 Evidence Bundle
## Cover Letter for IP Counsel Review

**From:** Martin Lepage, PhD — Chief Officer of Trust and Governance, PHAROS AI Governance Research & Practice; co-inventor.
**Co-inventor:** Danny Stocker — Principal Architect, InfraFabric Research.
**Bundle assembled:** 2026-04-21
**Closure addendum:** 2026-04-25
**Status:** `ready_with_bounded_gaps` for counsel review. **Not filing-ready.**

---

## What this bundle is

A self-contained evidence package supporting the PHAROS Invention Disclosure (V12). It contains the disclosure itself, every cited supporting document, a manifest of provenance, an editorial log of revisions applied during bundle preparation, an honest inventory of what is documented and what remains operator/counsel decision-open, and a short errata flagging internal inconsistencies in the V12 anchor that should be addressed before any filing draft is finalized.

---

## What's in the package

Fourteen files. One per title. All `.docx` or `.pdf`. Total ≈ 1.2 MB uncompressed.

**Anchor (PDF).**
- `00_PHAROS_Invention_Disclosure_v12.pdf` — joint-invention disclosure (Lepage + Stocker), method version v6.0, file revision v12. PDF chosen as the canonical signed-template version. Editable Word source preserved in vault archive (see "Audit-trail provenance" below).

**Cited supporting documents `01`–`08`.** Numbered in the order V12 §6 lists them. All `.docx`, polished from underlying `.md` / `.txt` sources by the 2026-04-23 revision pass.
1. `01_Recursive_AI_Governance_Very_Long_Narrative.docx`
2. `02_PHAROS_Master_SOP.docx`
3. `03_PHAROS_Recursive_Redesign_Passes_1-5_Claude+GPT.docx`
4. `04_PHAROS_Recursive_Redesign_Passes_1-5_Claude.docx`
5. `05_From_Recursive_Production_to_Governable_Method.docx`
6. `06_Codex_Governance_Case_Study_Blind_Leading_Automated.docx`
7. `07_InfraFabric_Architecture.docx`
8. `08_Mobius_Protocol.docx` — consolidated operational specification (originally five distinct descriptive sources; merged in the 2026-04-23 pass).

**Patent-language translation reference.**
- `09_PHAROS_method_translation_into_patent_language.docx` — earlier translation of the PHAROS method into the formal structure of an invention disclosure. Single-inventor framing (Lepage). Predates the joint-invention determination. Included as drafting-history reference; **not a substitute for the V12 anchor.**

**Counsel-facing context (read in this order).**
- `COVER_LETTER_FOR_COUNSEL.docx` — this file.
- `MANIFEST.docx` — bundle map and provenance summary.
- `FILING_FACTS_KNOWN_AND_OPEN.docx` — closure of the patent_readiness_review's "filing-governance facts unresolved" finding. Splits documented filing facts from operator/counsel-decision-open items.
- `ERRATA.docx` — three internal inconsistencies in the V12 anchor flagged for inventor sign-off (not silently corrected).

**Audit-trail provenance (NOT included in this bundle, preserved in vault archive at `EMERAULD/40_Archive/PHAROS Invention Disclosure Bundle Sources 2026-04-25/`):** the underlying `.md` / `.txt` sources for items 01–09 and the four counsel-facing context files; the editable `.docx` versions of the V12 disclosure anchor; the 2026-04-23 `REVISION_SUMMARY.md`, `editorial_log.md`, `deduplication_manifest.csv`, and the `batch_*.py` revision/conversion scripts; the `07_InfraFabric-reviewer-ready-2026-03-11.zip` archive from co-inventor Stocker. Available on request.

---

## Bundle history

- **2026-03-28:** post-audit gap-closure bundle produced; missing-dependency note flagged a translation file. (See EMERAULD wiki: `[[PHAROS Evidentiary Gap Closure Bundle]]`.)
- **2026-04-01:** dual-inventor determination locked in (Lepage + Stocker) per joint-invention finding.
- **2026-04-21:** V12 evidence bundle assembled at this path.
- **2026-04-23:** `REV_*.docx` revision pass run; deduplication and standardization applied.
- **2026-04-25:** missing translation file located and added (now `09_*`); FILING_FACTS, ERRATA, and this cover letter added; bundle frozen for counsel review.

---

## What I am asking counsel to do

1. **Review the V12 anchor** as the working disclosure for a joint-invention filing (Lepage + Stocker).
2. **Decide Section 5 — Option A vs Option B** — see "Open items" below. This is the highest-priority decision because it gates the disclosure body.
3. **Advise on the open items** — public-disclosure history, assignment instruments, jurisdiction strategy, signature/witness sequencing.
4. **Advise on the ERRATA items** — three internal inconsistencies in V12 that should be cleaned up before filing.
5. **Confirm or adjust the claim structure** recommended in `INTERNAL/Dossier Brevet Equinoxe/DOSSIER_MANIFEST.md` § "Claim Structure Recommendation."

---

## Open items requiring decision

### 1. Section 5 quantitative results — choose Option A or Option B (HIGHEST PRIORITY)

The disclosure body cites three quantitative figures (82% / 73% / 94%) without raw scoring tables in the bundle. The repository-level validator already tracks this as the bounded item `raw_scoring_evidence_absent`.

> **OPTION A:** Reconstruct and archive the raw scoring tables. If the bounded item closes, the figures stand as filed.
> **OPTION B:** Reframe as qualitative observations from the five-pass redesign. Remove specific percentages. The patentable novelty is architectural, not performance-based.

**Filing instruction from `DOSSIER_MANIFEST.md`:** *"Operator must decide before submission. Do not file with the current quantitative language unless Option A is completed."*

This decision has not been made. I am requesting counsel input on which option better protects the claim while staying truthful.

### 2. Public-disclosure history

No bundle artifact resolves whether the method, in any form, was publicly disclosed before the disclosure-finalization date. Candidate surfaces to verify: `pharos-ai.ca` site content history, `martin-lepage-site` repo history, LinkedIn posts, conference talks, paper preprints (`PHAROS_AIandEthics_Springer_FINAL.docx` is anonymized and not yet submitted; older drafts unverified), academic correspondence. I will run the disclosure-history checklist on counsel's instruction.

### 3. Assignment obligations

Two inventors, two distinct entities (PHAROS AI Governance Research & Practice; InfraFabric Research). Joint ownership across two entities has commercialization-licensing implications that vary by jurisdiction. No assignment instruments exist yet. I am requesting counsel guidance on ownership structure before producing them.

### 4. Jurisdiction strategy

Both inventors and entities are based in Montreal, Quebec, Canada. No jurisdiction-strategy artifact exists. Counsel-led decision: CIPO first / PCT timing / US strategy / EU/EPC strategy. I will capture the decision as a strategy memo in this bundle once made.

### 5. Inventor declarations and witness signatures

V12 pages 16–17 carry an `INVENTOR DECLARATIONS` page with four blank signature lines (two inventors, two witnesses). Sequencing relative to filing is per counsel guidance.

---

## What I have already done to make this disclosure stronger than v5

The `PHAROS_patent_readiness_review.md` (in `INTERNAL/Dossier Brevet Equinoxe/`) flagged six P1/P2 findings on the v5 draft:

| Finding | Disposition in V12 |
|---|---|
| Abstractness and enablement exposure (P1) | Addressed — V12 §4 specifies ten components with concrete modules, data records, and enforcement points. |
| Unsupported novelty language (P1) | Addressed — absolute prior-art assertions ("I have found no prior art") replaced; "eliminates evaluator judgment" language reframed. |
| Internal contradiction in rule mapping (P1) | Addressed — Stage / TC numbering normalized. (One residual labeling note in ERRATA E1.) |
| Testing claims outran disclosed support (P2) | **Open** — see Section 5 (Option A vs B above). |
| Residual-risk admissions not tied to mitigations (P2) | Partially addressed — V12 §7 lists seven residual risks; conversion to mitigation embodiments is the next drafting pass with counsel. |
| Filing-governance facts unresolved (P1) | Addressed by `FILING_FACTS_KNOWN_AND_OPEN.md` — documented what is known; surfaced what is operator-open. |

---

## Confidentiality and handling

This package is **Confidential — Patent Application Draft** as marked in the disclosure header. It contains pre-filing inventive content. Please handle accordingly and confirm receipt by secure channel.

---

## One closing note

Per the disclosure's own framing, the PHAROS method was applied to its own evidence chain. The bundle's `MANIFEST.md`, `REVISION_SUMMARY.md`, this file, `FILING_FACTS_KNOWN_AND_OPEN.md`, and `ERRATA.md` are the receipts. Nothing in the bundle is silently corrected; everything operator-decision-open is named as such; everything sourced is sourced. That is deliberate, and it is the same governance discipline the disclosure itself describes.

I look forward to your review.

— Martin Lepage, PhD
  Chief Officer of Trust and Governance
  PHAROS AI Governance Research & Practice
  Montreal, Quebec, Canada
